Page 100 - 《中国药房》2021年07期

tients with cancer：ASCO clinical practice guideline up- most，2012，108（2）：303-310.
date[J]. J Clin Oncol，2020，38（5）：496-520. [13] CHALAYER E，BOURMAUD A，TINQUAUT F，et al.
[ 2 ] 马军，秦叔逵，吴一龙，等.肿瘤相关静脉血栓栓塞症预防 Cost-effectiveness analysis of low-molecular-weight hepa-
与治疗指南：2019 版[J].中国肿瘤临床，2019，46（13）： rin versus aspirin thromboprophylaxis in patients newly
653-660. diagnosed with multiple myeloma[J]. Thromb Res，2016，
[ 3 ] STREIFF M，MILENTIJEVIC D，MCCRAE K R，et al. 145：119-125.
Healthcare resource utilization and costs associated with [14] DRANITSARIS G，SHANE L，BURGERS L，et al. Eco-
venous thromboembolism in cancer patients treated with nomic analysis comparing dalteparin to vitamin K antago-
anticoagulants[J]. J Med Econ，2019，22（11）：1134-1140. nists to prevent recurrent venous thromboembolism in pa-
[ 4 ] NCCN. NCCN clinical practice guidelines in oncology： tients with cancer having renal impairment[J]. Clin Appl
cancer-associated venous thromboembolic disease：2020. Thromb Hemost，2016，22（7）：617-626.
V1[EB/OL]. [2020-04-16]. https：//www.nccn.org/disclo- [15] CONNELL N T，ABEL G A，CONNORS J M. Low-mo-
sures/guidelinepanellisting.aspx. lecular weight heparin versus vitamin K antagonists for
[ 5 ] WANG T F，ZWICKER J I，AY C，et al. The use of direct the treatment of cancer-associated thrombosis：a cost-
oral anticoagulants for primary thromboprophylaxis in am- effectiveness analysis[J]. Thromb Res，2017，150：53-58.
bulatory cancer patients：guidance from the SSC of the [16] DRANITSARIS G，SHANE L G，CROWTHER M，et al.
ISTH[J]. J Thromb Haemost，2019，17（10）：1772-1778. Dalteparin versus vitamin K antagonists for the preven-
[ 6 ] 张嘉俊，杨琰茗，杨雅清，等. Ⅹa因子抑制剂预防和治疗 tion of recurrent venous thromboembolism in patients
癌症患者静脉血栓栓塞有效性和安全性的Meta分析[J]. with cancer and renal impairment：a Canadian pharmaco-
中国药房，2020，31（6）：729-733. economic analysis[J]. Clinicoecon Outcomes Res，2017，
[ 7 ] HUSEREAU D，DRUMMOND M，PETROU S，et al. Con- 9：65-73.
solidated health economic evaluation reporting standards [17] DRANITSARIS G，SHANE L G，GALANAUD J P，et al.
（CHEERS）：explanation and elaboration：a report of the Dalteparin or vitamin K antagonists to prevent recurrent
ISPOR health economic evaluation publication guidelines venous thromboembolism in cancer patients：a patient-
good reporting practices task force[J]. Value Health，2013， level economic analysis for France and Austria[J]. Sup-
16（2）：231-250. port Care Cancer，2017，25（7）：2093-2102.
[ 8 ] RAJAN R，GAFNI A，LEVINE M，et al. Very low-dose [18] CONNELL N T，CONNORS J M. Cost-effectiveness of
warfarin prophylaxis to prevent thromboembolism in edoxaban versus dalteparin for the treatment of cancer-
women with metastatic breast cancer receiving chemothe- associated thrombosis[J]. J Thromb Thrombolysis，2019，
rapy：an economic evaluation[J]. J Clin Oncol，1995，13 48（3）：382-386.
（1）：42-46. [19] LI A，MANOHAR P M，GARCIA D A，et al. Cost effec-
[ 9 ] AVRITSCHER E B，CANTOR S B，SHIH Y C，et al. Cost- tiveness analysis of direct oral anticoagulant（DOAC）ver-
minimization analysis of low-molecular-weight heparin sus dalteparin for the treatment of cancer associated
（dalteparin）compared to unfractionated heparin for inpa- thrombosis（CAT）in the United States[J]. Thromb Res，
tient treatment of cancer patients with deep venous throm- 2019，180：37-42.
bosis[J]. Support Care Cancer，2004，12（7）：531-536. [20] DU J，WU B. New oral anticoagulants for thromboprophy-
[10] AUJESKY D，SMITH K J，CORNUZ J，et al. Cost-effec- laxis in patients with cancer receiving chemotherapy：an
tiveness of low-molecular-weight heparin for secondary economic evaluation in a Chinese setting[J]. Clin Drug In-
prophylaxis of cancer-related venous thromboembo- vestig，2020，40（7）：653-663.
lism[J]. Thromb Haemost，2005，93（3）：592-599. [21] LI A，CARLSON J J，KUDERER N M，et al. Cost-effec-
[11] DRANITSARIS G，VINCENT M，CROWTHER M. Dal- tiveness analysis of low-dose direct oral anticoagulant
teparin versus warfarin for the prevention of recurrent ve- （DOAC）for the prevention of cancer-associated thrombo-
nous thromboembolic events in cancer patients：a pharma- sis in the United States[J]. Cancer，2020，126（8）：1736-
coeconomic analysis[J]. Pharmacoeconomics，2006，24 1748.
（6）：593-607. [22] LOPES D G，TAMAYO A，SCHIPP B，et al. Cost-effec-
[12] PISHKO A M，SMITH K J，RAGNI M V. Anticoagulation tiveness of edoxaban vs low-molecular-weight heparin
in ambulatory cancer patients with no indication for pro- and warfarin for cancer-associated thrombosis in Brazil
phylactic or therapeutic anticoagulation：a cost-effective- [J]. Thromb Res，2020，196：4-10.
ness analysis from a U.S. perspective[J]. Thromb Hae- [23] LEVINE M，HIRSH J，GENT M，et al. Double-blind ran-

·858 · China Pharmacy 2021 Vol. 32 No. 7 中国药房 2021年第32卷第7期